Figure 4

AP2M1 increases stemness. A) CytoTRACE2 stemness score for normal and malignant cell states from scRNA‐seq data. The cells are grouped by the expression of AP2M1 and by cell compartments. Higher scores suggest greater stem‐like characteristics. The p‐values are as follow, ^*p < .05, ^**p < 0.01, ^***p < .001. B,C) Assays measuring changes in stemness markers. CD34, CD133, CD123, and CD44 were used as indicators of primitive cellular properties. The alterations were assessed in both control and AP2M1‐overexpressing cells, as well as following drug treatment, at protein (B) and mRNA levels (C). D) mRNA expression levels of stemness markers in control and AML patient samples. E) Correlation between AP2M1 and stemness‐related genes in bone marrow samples from healthy individuals and AML patients. Only the significant correlation coefficients are reported. F) WISH analysis and lateral view imaging of cmyb expression in the CHT of 72 hpf zebrafish embryos injected with 900 pg nL⁻¹ of ap2m1a mRNA and WT zebrafish embryos.